Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

PolandBack to Poland

Clinical trials in Łomianki

13 clinical trials in Łomianki, Poland. Every trial is listed in the EU Clinical Trials Register and updated daily.

PolandOur site in PolandBadaniaKliniczne.pl(opens in a new tab)
Łomianki at a glance
13
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

13 trials in Łomianki

Open in trial search

Pneumococcal immunisation

Recruiting

Safety of PF-07872412 versus 20‑valent pneumococcal conjugate vaccine in healthy infants for prevention of pneumococcal disease

Registered drugNo placebo
Countries:PolandPoland
  • Participants:0–17 years
  • Substances:PF-07831695
  • Sponsor:Pfizer Inc.

Type 2 diabetes mellitus+1

Recruiting

A study on the effectiveness of cagrilintide and semaglutide for weight management in children and adolescents with obesity

Investigational
Countries:PolandPoland
  • Participants:0–17 years
  • Substances:Cagrilintide
  • Sponsor:Novo Nordisk A/S

Respiratory syncytial virus immunisation

Not yet recruiting

Safety, Tolerability and Immunogenicity of RSV prefusion F protein 847a and 847b Vaccine in Children 5‑17 Years at High Risk of RSV Disease

Registered drug
Countries:PolandPoland
  • Participants:0–17 years
  • Substances:RESPIRATORY SYNCYTIAL VIRUS, SUBGROUP A, STABILIZED PREFUSION F PROTEIN 847A
  • Sponsor:Pfizer Inc.

Pneumococcal immunisation

Not yet recruiting

Safety and immune response of PF-07872412 compared with 20-valent pneumococcal conjugate vaccine for pneumococcal disease in healthy children and adolescents

Registered drugNo placebo
Countries:PolandPoland
  • Participants:0–17 years
  • Substances:PF-07831695
  • Sponsor:Pfizer Inc.

Pyelonephritis acute

Not yet recruiting

Study on Cefepime and Enmetazobactam for Children with Complicated Urinary Tract Infections, Including Acute Pyelonephritis

Registered drugNo placebo
Countries:PolandPoland
  • Participants:0–17 years
  • Substances:Cefepime

Respiratory syncytial virus infection

Not yet recruiting

Study on the Safety and Tolerability of Sisunatovir in Infants and Children with RSV Infection

Investigational
Countries:PolandPoland
  • Participants:0–17 years
  • Substances:Sisunatovir
  • Sponsor:Pfizer Inc.

Lyme disease

Not recruiting

Study on the Effectiveness and Safety of the VLA15 Vaccine for Preventing Lyme Disease in Healthy Individuals Aged 5 and Older

Registered drug
Countries:PolandPoland
  • Participants:0–17 years · 18–64 years · 65+ years · Healthy volunteers
  • Substances:Sodium chloride solution 0.9%
  • Sponsor:Pfizer Inc.

Pneumococcal immunisation

Not recruiting

Study on the Safety and Immune Response of a 21-Valent Pneumococcal Conjugate Vaccine in Healthy Infants and Toddlers

Registered drugNo placebo
Countries:PolandPoland
  • Participants:0–17 years · Healthy volunteers
  • Substances:Pneumococcal oligosaccharide serotype 18C conjugated to CRM197
  • Sponsor:Sanofi Pasteur Inc.

Meningococcal infection

Not recruiting

Study on the Safety and Immune Response of MenACYW Conjugate Vaccine Compared to a Drug Combination in Healthy Infants and Toddlers

Registered drugNo placebo
Countries:PolandPoland
  • Participants:0–17 years · Healthy volunteers
  • Substances:N. Meningitidis Group C (Strain C11) Polysaccharide (De-O-Acetylated) Conjugated To Tetanus Toxoid
  • Sponsor:Sanofi Pasteur

Urinary tract infection+1

Not recruiting

Study of meropenem-vaborbactam safety and effectiveness in children aged 3 months to 12 years with complicated urinary tract infection or acute pyelonephritis

InvestigationalNo placebo
Countries:PolandPoland
  • Participants:0–17 years
  • Substances:Meropenem
  • Sponsor:Rempex Pharmaceuticals Inc.

Pneumococcal infection

Not recruiting

Study on the Safety and Immune Response of V116 Vaccine in Children and Adolescents at Higher Risk for Pneumococcal Disease

Registered drugNo placebo
Countries:PolandPoland
  • Participants:0–17 years
  • Substances:ABC-15A-116
  • Sponsor:Merck Sharp & Dohme LLC

Cystic fibrosis

Not recruiting

Study on Long-term Safety of VX-121, Tezacaftor, and Deutivacaftor in Patients with Cystic Fibrosis

Registered drugNo placebo
Countries:PolandPoland
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Deutivacaftor
  • Sponsor:Vertex Pharmaceuticals Inc.

Other cities in Poland

The busiest research cities in the country

All 239 cities in Poland

Clinical research in Łomianki

What the registry says about research in the country

01 Infectious Disease Prevention

Innovative research focusing on meningococcal infection prevention through vaccine development, evaluating immunogenicity and safety in young populations. Studies examine protective responses against multiple bacterial serogroups.

  • Meningococcal Vaccination
  • Pediatric Immunology
  • Preventive Medicine

These trials aim to enhance protection against serious bacterial infections in infants and toddlers.

02 Respiratory Medicine

Groundbreaking studies addressing respiratory syncytial virus infections and cystic fibrosis, testing new therapeutic approaches for these challenging conditions.

  • RSV Treatment
  • Cystic Fibrosis Management
  • Pediatric Respiratory Care

Research focuses on innovative treatments to improve outcomes in respiratory conditions affecting young patients.

03 Urological Research

Clinical investigations examining treatments for complicated urinary tract infections, including specialized studies on acute pyelonephritis in pediatric populations.

  • Urinary Tract Infections
  • Pediatric Urology
  • Antimicrobial Therapy

These studies evaluate new therapeutic options for complex urological conditions in children.

Back to PolandAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.